AKBA Aug 2024 1.000 call
| Previous Close | 0.1700 |
| Open | 0.1000 |
| Bid | 0.0500 |
| Ask | 0.1500 |
| Strike | 1.00 |
| Expire Date | 2024-08-16 |
| Day's Range | 0.1000 - 0.1700 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 243 |
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted five newly-hired employees options to purchase an aggregate of 517,000 shares of Akebia's common stock on June 28, 2024, including an option to purchase 500,000 shares to Erik Ostrowski, Akebia's newly hired Chief Financial Officer and Chief Business Officer. The options were granted as an inducement material to each such employee entering into
- PR Newswire
Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in the H.C. Wainwright 3rd Annual Kidney Virtual Conference on Monday, July 15, 2024. Mr. Butler will present at 9:30 a.m. ET to provide updates on the progress of commercial launch activities for Vafseo® (vadadustat) Tablets.
- PR Newswire
Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Erik Ostrowski as Senior Vice President, Chief Financial Officer and Chief Business Officer. Mr. Ostrowski is an experienced biotech executive with a diverse background spanning industry leadership roles, board service and investment banking.
